WP Explorer — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Gradalisgradalisinc.comin𝕏Jun 2025SEC filingmedium confidence
Gradalis is a biotechnology company developing personalized cancer immunotherapies, including its Vigil platform for multiple advanced cancer indications.
BiotechHealthtechCarrollton, US
John Nemunaitis(Co-Founder & Chief Scientific Officer)David M. Shanahan(Executive Officer, Director)Mark Early(Executive Officer)Ernest Bognar(Executive Officer)Gladice Wallraven(Executive Officer)Joe Cunningham, M.D.(Director)
Board seatJoseph F. Berry· per SEC Form D · $30M raise · filed Jun 2025
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.